

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SoftMedx Healthcare Limited

京玖醫療健康有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

ELECTION OF LANGUAGE AND MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS

The Company would like to offer to Shareholders options in the language and means of receipt of future Corporate Communications.

INTRODUCTION

In support of the Stock Exchange's "Proposal to Expand the Paperless Listing Regime" and to offer the Shareholders to receive Corporate Communications electronically to reduce paper consumption, the Company would like to enquire the Shareholders about their preferred options on the language (in English version only, in Chinese version only, or in both English and Chinese versions) and the means of receipt (by Website Version or in printed copies) of future Corporate Communications. Shareholders are recommended to elect for the Website Version to support the environment.

ARRANGEMENTS

A letter together with a reply form will be sent by the Company on 25 April 2024 to the Shareholders for them to select one of the following options:

- Option 1: to access the Website Version of future Corporate Communications and receive notification of the publication of Corporate Communications on the websites of the Stock Exchange and the Company; or
- Option 2: to receive printed English and Chinese versions of future Corporate Communications; or
- Option 3: to receive printed English version of future Corporate Communications; or
- Option 4: to receive printed Chinese version of future Corporate Communications.

The reply form should be duly completed, signed and returned to the Company by post at Level 38, Infinitus Plaza, 199 Des Voeux Road Central, Hong Kong on or before 24 May 2024. If the Company does not receive from the Shareholder a duly completed and signed reply form or a written response indicating an objection to receiving Corporation Communications in Website Version by then, such Shareholder (i) will be deemed to consent to accessing the Website Version of future Corporate Communications; and (ii) will receive future notifications and Actionable Corporate Communications by email or by post.

Those Shareholders who are in support of the environment and elect to access the Website Version of future Corporate Communications please provide an email address in the reply form for receiving future notifications and Actionable Corporate Communications by email; otherwise, the Company will still be required to send the notifications and the Actionable Corporate Communications in printed form to them.

For Shareholders who choose to receive Corporate Communications in printed form, the Company will send the printed copies to them by post. Shareholders may change their election of language and means of receipt of future Corporate Communications by prior written notice of not less than seven days to the Company. If a Shareholder has elected (or is deemed to elect) to access the Website Version of future Corporate Communications but subsequently wishes to receive printed copies, the Company will provide the printed copies upon request.

GENERAL

Trading in the shares of the Company will continue to be suspended pending fulfilment of the resumption conditions. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

DEFINITIONS

The following terms shall mean:

“Actionable Corporate Communications”	Corporate Communications from the Company that seek instruction from Shareholders, including election forms for dividend payment, excess application forms of rights issue or open offer, provisional allotment letters of rights issue, application forms for assured entitlement of open offer, and acceptance forms relating to takeovers, mergers and share buy-backs
“Company”	SoftMedx Healthcare Limited, a company incorporated in Hong Kong with limited liability whose issued shares are listed on the Main Board of the Stock Exchange
“Corporate Communications”	documents issued by the Company for information or action of Shareholders, including interim and annual reports, notices of meetings, listing documents, circulars and proxy forms
“Shareholders”	holders of the shares of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Website Version”	the version of the Corporate Communications in electronic form published on the websites of the Stock Exchange and the Company

For and on behalf of the board of
SoftMedx Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 24 April 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Cheung Wai Kwan and Mr. Wang Jianguo as executive directors; and Ms. Hu Xuezheng, Mr. Lin Pinzhao and Mr. Yiu Chun Wing as independent non-executive directors.